Inactive Instrument

News Correvio Pharma Corp Toronto S.E.

Equities

CA14159U3010

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Mark Corrigan Departs as CEO from Correvio Pharma Corp	20-05-27	CI
Justin Renz, CFO Departs from Correvio Pharma Corp	20-05-27	CI
Correvio Pharma Corp. Announces Management Changes	20-05-27	CI
Mercury Pharma Group Limited completed the acquisition of Correvio Pharma Corp..	20-05-26	CI
Correvio Pharma : Obtains Final Order for Plan of Arrangement	20-05-21	PR
Correvio Pharma : Announces Results from Annual General and Special Meeting of Securityholders	20-05-15	PR
Transcript : Correvio Pharma Corp. - Shareholder/Analyst Call	20-05-15
Correvio Pharma : Leading Independent Proxy Advisory Firm Glass Lewis Recommends That Correvio Shareholders Vote for the Arrangement With ADVANZ PHARMA	20-05-06	PR
Correvio Pharma Corp. Postpones Announcement of Financial Statements for the First Quarter Ended March 31, 2020	20-05-04	CI
Correvio Pharma : Announces Postponement of Its First Quarter 2020 Financial Results Due to Impacts From COVID-19	20-05-04	PR
Correvio Pharma : Leading Independent Proxy Advisory Firm ISS Recommends That Correvio Shareholders Vote for the Arrangement with ADVANZ PHARMA	20-05-01	PR
Correvio Pharma : Obtains Interim Order For Plan Of Arrangement	20-04-08	PR
Correvio Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-30	CI
Correvio Pharma : Reports Full Year 2019 Financial Results	20-03-30	PR
Correvio Pharma Corp. Auditor Raises 'Going Concern' Doubt	20-03-29	CI
CORREVIO PHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Correvio Pharma Corp. - CORV	20-03-20	BU
Correvio Pharma : ADVANZ PHARMA to Acquire Correvio	20-03-16	PR
Mercury Pharma Group Limited entered into an arrangement agreement to acquire Correvio Pharma Corp. for $21.3 million.	20-03-15	CI
Correvio Pharma : Receives NASDAQ Notification Regarding Deficiencies In Minimum Bid Price And Market Value Of Listed Securities	20-01-28	PR
Correvio Pharma : Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events	19-12-24	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Correvio Pharma Corp Toronto S.E.

Equities

CA14159U3010

Summary

Filters